Drug Database
Back to search

United Kingdom· GB-APID-31074311000001101

Intuniv 2mg modified-release tablets

A guanfacine product containing guanfacine, registered in United Kingdom by Takeda UK Ltd. The same ATC class is registered in 14 of our 19 countries.

ATC C02AC02

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedIntuniv 2mg modified-release tabletsATCC02AC02REGISTER NO.GB-APID-3107431100000…PACKS LISTED2CHECKEDSeptember 13, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about guanfacineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Guanfacine is registered in 14 of 19 countries.

Countries holding a registration under ATC C02AC02 (guanfacine), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 8 of them publish a price we can compare per daily dose
Search guanfacine products by name

Guanfacine · ATC C02AC02

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of guanfacine costs, country by country.

Normalised to the WHO defined daily dose (3 mg), the median price runs from $0.21 in United States to $7.74 in Switzerland — a ×37 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Guanfacine · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$7.74
  • US United States$0.21 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Guanfacine
Manufacturer
Takeda UK Ltd
Country
United Kingdom (GB)
ATC code
C02AC02
ATC class
Guanfacine
Defined daily dose
3 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    5022690009212
  • gtin
    05060147024227

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

163 interactions on record for guanfacine.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check guanfacine against other medicinesHow interaction checks work

Guanfacine · interactions on record

163 records

  • 30 severe
  • 133 moderate

Most severe, free to view

  • AprepitantA04AD12severe
  • DexamethasoneH02AB02severe
  • KetoconazoleH02CA03severe
  • ChloramphenicolJ01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Guanfacine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All guanfacine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Germany · Guanfacin Neuraxpharm
  • Iceland · Intuniv, Paxneury
  • Liechtenstein · Intuniv, Paxneury
  • Norway · Intuniv, Paxneury

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ecb1a6ad-2f65-4e62-a896-8a8dad0e50da
GET /v1/drugs/ecb1a6ad-2f65-4e62-a896-8a8dad0e50da?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "31074311000001101",
  "desc": "Intuniv 2mg modified-release tablets (Takeda UK Ltd)",
  "form": "Modified-release tablet",
  "vpid": "31087711000001100",
  "source": "dmd",
  "vtm_id": "776162002",
  "strength": "2 mg",
  "substance": "Guanfacine",
  "ingredient": "Guanfacine hydrochloride",
  "supplier_code": "3811601000001107"
}
API referenceMCP serverPlans

See everything about guanfacine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console